😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Two plead guilty to insider trading in Kodak before Trump loan announcement

Published 04/03/2024, 01:37 PM
Updated 04/03/2024, 02:00 PM
© Reuters. FILE PHOTO: A worker cleans a Kodak booth at the Las Vegas Convention Center in preparation for 2019 CES in Las Vegas, Nevada, U.S. January 6, 2019. REUTERS/Steve Marcus/File Photo
KODK
-

By Jonathan Stempel

NEW YORK (Reuters) - A former pharmaceutical executive and his cousin pleaded guilty on Wednesday to insider trading in Eastman Kodak, based on tips that the company was arranging a surprise $765 million loan from the Trump administration to make drug ingredients.

Andrew Stiles and Gray Stiles each admitted to one count of securities fraud at a hearing before U.S. District Judge Ronnie Abrams in Manhattan.

Both defendants were accused of buying Kodak shares in anticipation of the U.S. International Development Finance Corp loan to the former photography giant, and selling them after the loan was announced on July 28, 2020.

Prosecutors said this led to more than $500,000 of illegal profit for Andrew Stiles and more than $700,000 for Gray Stiles.

Lawyers for the defendants did not immediately respond to requests for comment.

Andrew Stiles was a vice president at Phlow, a Richmond, Virginia-based medicine supply chain company working with Kodak, when he allegedly learned about the loan and tipped his cousin.

An indictment included coded text messages between the pair, including where Gray Stiles referred to the loan as "film we sent off a few weeks ago to get developed."

Sentencing is scheduled for July 24.

Andrew Stiles, of Charleston, South Carolina, could face 21 to 27 months in prison under his plea agreement. Gray Stiles, of Richmond, could face 10 to 16 months. Fines are also possible.

Shares of Rochester, New York-based Kodak soared to $60 from $2.62 within two days of the loan's announcement, as the company sought to remake itself.

At a press briefing, Trump called Kodak a "great American company" with "one of the great brands in the world," and said the loan would give it the capacity to produce up to 25% of the active ingredients needed to produce generic drugs domestically.

"We must never be reliant on a foreign nation for America's medical or other needs," Trump said.

The loan was never issued.

Both defendants also faced related civil charges by the U.S. Securities and Exchange Commission. That case has been on hold pending a resolution of the criminal case.

© Reuters. FILE PHOTO: A worker cleans a Kodak booth at the Las Vegas Convention Center in preparation for 2019 CES in Las Vegas, Nevada, U.S. January 6, 2019. REUTERS/Steve Marcus/File Photo

Kodak and Phlow were not charged.

The case is U.S. v. Stiles et al, U.S. District Court, Southern District of New York, No. 23-cr-00098.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.